Wealth Enhancement Advisory Services »

Crispr Therapeutics shares owned by Wealth Enhancement Advisory Services

Quarter-by-quarter ownership of Crispr Therapeutics (CRSP) shares owned by Wealth Enhancement Advisory Services from 13F filings

Historical chart of Wealth Enhancement Advisory Services investment in Crispr Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Crispr Therapeutics held by Wealth Enhancement Advisory Services consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Crispr Therapeutics by Wealth Enhancement Advisory Services

Quarter filed Position value Share count Share price at filing
2024-06-30 $1.7M 32k 54.01
2024-03-31 $931k 14k 68.16
2023-12-31 $886k 14k 62.60
2023-09-30 $471k 10k 45.39

More positions owned by Wealth Enhancement Advisory Services

Ishares Tr Core S&p500 Etf (IVV)
Apple (AAPL)
Ishares Tr Core Us Aggbd Et (AGG)
Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)
Ishares Tr Msci Intl Moment (IMTM)
Vanguard Intl Equity Index F Ftse Emr Mkt Etf (VWO)
Alps Etf Tr Smith Core Plus (SMTH)
Schwab Strategic Tr Fundamental Intl (FNDF)
Amazon (AMZN)
Invesco Exch Traded Fd Tr Ii Dorsey Wrgt Smlc (DWAS)
J P Morgan Exchange Traded F Us Momentum (JMOM)
Invesco Exchange Traded Fd T S&p500 Quality (SPHQ)
American Centy Etf Tr Us Large Cap Vlu (AVLV)
Schwab Strategic Tr Us Lrg Cap Etf (SCHX)

View all positions for Wealth Enhancement Advisory Services

Top funds holding Crispr Therapeutics

Capital Research and Management Company - Division 3
ARK Investment Management
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
BlackRock
BlackRock
T. Rowe Price Investment Management
State Street Corporation
Vanguard Group
NEA Management Company
Citadel Advisors
EcoR1 Capital
Susquehanna International
Bank of America Corporation
Sr One Capital Management

View all funds holding Crispr Therapeutics